Clinical trial data and emerging strategies: HER2-positive breast cancer
Sonia Pernas1,2, Sara M Tolaney3,4
1Department of Medical Oncology, Catalan Institute of Oncology - ICO, L'Hospitalet de Llobregat, Barcelona, Spain.
Abstract:
A deeper insight into tumor biology and HER2 signaling has led to the development of novel anti-HER2 drugs that have significantly improved the prognosis of patients with HER2-positive breast cancer. The breast cancer immune microenvironment has emerged as a potential prognostic factor. Moreover, the host immune system not only seems to play a critical role in the prognosis of HER2-positive breast cancer, but also seems to modulate treatment response to some HER2-targeted agents. Here, we review the latest evidence of the role of immunotherapy in HER2-positive breast cancer and present emerging strategies.
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview


